Expansion of Urine Behavioral Health Drug Testing, AcuRiseID™

Aegis Sciences Corporation, a leading healthcare company that provides innovative medication adherence testing, is pleased to announce the expansion of…

Increase in Drug Overdoses Due to Synthetic Opioids During the COVID-19 Pandemic

The challenges of the COVID-19 pandemic have continued to affect populations across the world in numerous ways. Finding a solution to the pandemic has…

What Did My Patient Actually Take? An Overview of Dextromethorphan/Levorphanol Results

Accurate interpretation of dextromethorphan/levorphanol results should take into account the patient’s prescription and over-the-counter (OTC) drug regimen…

Drug-Drug Interactions (DDI) amidst the Pandemic and Opportunities for Objective DDI Monitoring via Oral Fluid Testing

The Coronavirus Disease 19 (COVID-19) pandemic has introduced many different challenges to the world this year. Economic, technologic, and healthcare issues…

COVID-19 and Its Impact on Persons with Mental Illness and Substance Use

The COVID-19 pandemic has brought significant challenges to both healthcare systems and public health. Social distancing, disruption of healthcare services,…

Emerging Data on Novel Psychoactive Substances and Clinical Effects

Emerging Data on Novel Psychoactive Substances and Clinical Effects Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive…

Designer Opioids and Benzodiazepines

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs which vary significantly…